What Sildenafilo Cinfa treats: main uses and benefits

The medicine is generally applied across therapeutic domains that require supportive symptom management, addressing two distinct clinical presentations. Its applications fall primarily under two domains.

Sildenafilo Cinfa is considered relevant for addressing symptoms of Erectile Dysfunction (ED), and may be part of symptomatic management for Pulmonary Arterial Hypertension (PAH). The medicine is applicable in clinical settings that involve acute or disruptive symptom patterns related to sexual function, and chronic, heightened symptom patterns related to pulmonary vascular conditions.

For patients experiencing difficulties with achieving or maintaining an erection, the medication provides supportive relief that helps maintain a sense of stability when symptoms are more noticeable. For those with PAH, it helps address symptom clusters that create noticeable interference with daily comfort, such as shortness of breath and reduced exercise capacity. This use is relevant in contexts involving heightened systemic burden.

“The medicine is used when short-term symptomatic assistance is needed to help manage functional difficulties or when continuous support is required for chronic conditions.”

Quick Fact: Symptom Management Across Key Domains

This supportive therapeutic benefit contributes to easing the overall symptom load and may assist with easing distress and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Sildenafilo Cinfa?

Sildenafilo Cinfa is officially approved for adult males with Erectile Dysfunction (ED) and adults and children aged 1 year and over with Pulmonary Arterial Hypertension (PAH). The regulatory documentation strictly defines who can use the medicine and who is absolutely excluded.

---

Populations for whom use is contraindicated

The medicine must not be used by patients taking organic nitrates in any form or guanylate cyclase stimulators (e.g., riociguat). Absolute non-eligibility applies to patients with a history of vision loss due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), severe hypotension (BP < 90/50 mmHg), hereditary degenerative retinal disorders, or a recent stroke or myocardial infarction. Use is also contraindicated if sexual activity is inadvisable due to existing cardiovascular status.

---

Eligibility-related restrictions

For the ED indication, use is not indicated in individuals under 18 years. Patients with severe renal impairment or hepatic impairment should use the medicine conditionally. Caution is also advised for geriatric patients and individuals with conditions predisposing to priapism (e.g., sickle cell anaemia or multiple myeloma). Use during pregnancy or lactation is generally not indicated or requires a specific risk assessment.

Interactions with other medicines and products

Sildenafilo Cinfa’s official interaction profile is characterized by pharmacodynamic risks of additive blood pressure lowering effects and pharmacokinetic risks involving the drug's metabolism. All constraints are based strictly on regulatory document findings.

---

Contraindicated Combinations

Classification	Interacting Agents	Rationale
Contraindicated	Organic Nitrates (e.g., Nitroglycerin) or Nitric Oxide Donors	Potentiation of hypotensive effects, resulting in a risk of severe, life-threatening hypotension [FDA Label, EMA SmPC].
Contraindicated	Riociguat (sGC Stimulator)	Risk of additive hypotension when combined with PDE5 inhibitors [FDA Label, EMA SmPC].

---

Officially Documented Interactions

Interaction Type	Interacting Agents	Official Statement / Constraint
Pharmacokinetic (CYP3A4)	Ritonavir (Strong CYP3A4 Inhibitor)	Co-administration causes a documented 11-fold increase in exposure (AUC). Requires strict dose limitation [EMA SmPC].
Pharmacodynamic	Alpha-Blockers (e.g., Doxazosin)	May lead to additive hypotensive effects; the highest risk is documented to occur within 4 hours post-sildenafil dosing [EMA SmPC].
Food/Absorption	High-Fat Meal	Causes a reduced rate of absorption, delaying the time to reach maximum plasma concentration (Tmax) [FDA Label].

---

Population-Specific Notes

Official documents note that Sildenafil clearance is reduced in patients with severe hepatic or renal impairment, which may increase the medicine's effects. Additionally, an increased incidence of epistaxis (nosebleeds) has been reported in patients taking Sildenafil with a concomitant oral vitamin K antagonist [FDA Label].

Targeted PDE5 Enzyme Inhibition

Sildenafilo Cinfa is a highly selective Phosphodiesterase type 5 ( PDE5) inhibitor, meaning its primary action is to prevent the PDE5 enzyme from hydrolyzing the key signaling molecule, cyclic Guanosine Monophosphate ( cGMP). This molecular action sustains the concentration of cGMP within the smooth muscle cells of the target vasculature, preventing the molecule from being rapidly degraded.

---

Augmentation of the NO- cGMP Signaling Cascade

The drug operates as a functional augmenter of the body’s natural Nitric Oxide ( NO)– cGMP pathway, supporting the local signaling that governs vessel tone. By sustaining cGMP levels, the drug supports the cascade of events that results in the relaxation of vascular smooth muscle and the resultant vasodilatation (vessel widening).

---

Mechanistic Contingency and Functional Dependency

The mechanistic effect of Sildenafil is contingent upon the local release of Nitric Oxide to initiate cGMP production. The drug supports and prolongs the NO signal but cannot trigger it independently. This constraint defines its scope as a localized augmentation of an existing physiological response.

How to Use Sildenafilo Cinfa — Official Administration Guidelines

Sildenafilo Cinfa, which contains the active ingredient sildenafil, is administered according to two distinct official usage patterns based on the condition being addressed: intermittent use for Erectile Dysfunction (ED) and continuous use for Pulmonary Arterial Hypertension (PAH).

Property	Administration Details
Administration Route	Primarily oral (tablet, suspension). An intravenous (IV) injection form is approved for use in the PAH context when the oral route is not feasible.
Dosing Schedule (ED)	The recommended starting dose is 50 mg, taken as needed. The dose range is 25 mg to 100 mg, with a maximum frequency of once per day.
Dosing Schedule (PAH)	The recommended dose is 20 mg administered three times a day (TID). Doses may be adjusted up to 80 mg TID or given as a 10 mg IV bolus TID.
Timing & Context (ED)	The tablet is typically taken one hour before activity, ranging from 30 minutes to 4 hours prior. Taking the dose with food may delay the onset of its functional effect. Effectiveness requires sexual stimulation.
Dosing Adjustments	A reduced starting dose of 25 mg should be considered for patients with severe hepatic or renal impairment (ED context). The maximum dose is restricted to 25 mg within 48 hours when co-administered with ritonavir.

The official instructions mandate strict adherence to these dosing and timing constraints. For PAH, the TID doses must be administered approximately 4 to 6 hours apart to maintain the required continuous therapeutic exposure. These established parameters define the protocol for use of the medicine.

Evidence for Use in Erectile Dysfunction (ED)

The core research for Sildenafilo Cinfa in Erectile Dysfunction involved high-volume short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the study compound against a placebo. Researchers monitored changes in a condition characterized by functional limitations, focusing on outcomes reflecting daily functioning and patient-reported outcomes. Studies monitored the difference in measured outcomes between the study agent and the placebo, reporting patterns related to measured outcomes observed in the group receiving the study agent. What is known applies mainly to the adult male populations studied, including individuals with ED associated with conditions like diabetes. Data are still emerging, and research provides limited insight into long-term outcomes.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research for Sildenafilo Cinfa in PAH involved short- to intermediate-term RCTs, focusing on conditions marked by functional limitations and physiological strain. Studies explored how symptoms evolved by primarily measuring exercise capacity (6MWD) and outcomes related to systemic or functional imbalance. Studies reported patterns related to these measured outcomes observed in the group receiving the study agent. Given the chronic nature of PAH, the follow-up durations of the pivotal trials were limited, meaning limited information for long-term outcomes exists.

---

Research Gaps and Limitations

The core clinical evidence for both indications was derived from trials with relatively limited follow-up durations, meaning limited information for long-term effects exists based on initial controlled research. Research explored use in special populations, such as children with PAH; however, subsequent post-market evidence indicated variability in findings associated with certain doses in children. As a result, specific regulatory guidance was put in place. Comparative evidence against all available treatments is also lacking for certain research scenarios, highlighting areas where research is ongoing.

Key Studies & References

1. A meta-regression analysis of treatment effect modifiers on the response to sildenafil in men with erectile dysfunction

Common questions about Sildenafilo Cinfa (FAQ)

---

Q: Why does Sildenafilo Cinfa sometimes cause facial flushing or headache?

A: The medicine works by relaxing and widening blood vessels throughout the body, a process known as vasodilatation. Official side effect data indicates that common reactions include headache and flushing (redness of the face and neck). These effects are understood to be related to the drug's mechanism of action on blood vessel smooth muscle.

---

Q: What is the risk of Sildenafilo Cinfa causing a sudden drop in blood pressure?

A: Sildenafilo Cinfa can cause a decrease in blood pressure (hypotension) due to its vasodilating effect. This risk is notably high when the medicine is taken with other blood pressure-lowering drugs, such as nitrates, and this combination is strictly contraindicated by regulatory bodies. Official product information notes that severe, sudden drops in blood pressure may occur in susceptible individuals.

---

Q: Can Sildenafilo Cinfa be used by people with diabetes or high blood pressure?

A: Clinical research for the erectile dysfunction indication included individuals who had associated conditions like diabetes. Caution is mentioned in regulatory documents regarding the concomitant use of sildenafil with certain medications used to manage high blood pressure, such as alpha-blockers. This is because combining these medicines may result in additive blood pressure lowering effects.

---

Q: Is Sildenafilo Cinfa safe for long-term or ongoing use?

A: Sildenafil, the active ingredient, is indicated for continuous, long-term use in the treatment of Pulmonary Arterial Hypertension (PAH). For the treatment of erectile dysfunction, official research evidence provided limited information regarding the safety and effectiveness of the medication beyond the short-term duration of the initial controlled trials.

---

Q: What is priapism, and why is it a concern with Sildenafilo Cinfa?

A: Priapism is defined in official safety information as a rare, serious side effect: a sustained, painful erection lasting longer than four hours. Caution is specifically advised for patients who have pre-existing conditions that might predispose them to this event, such as certain blood cell disorders like sickle cell anaemia.

---

Q: Why is Sildenafilo Cinfa generally not recommended for use in children?

A: For the treatment of PAH, the medication is officially approved for use in children aged 1 year and over, following specific dose guidance. However, it is not indicated for the treatment of erectile dysfunction in individuals under 18. Regulatory documents mention that specific guidance is necessary due to variable clinical findings associated with certain doses in younger populations.

---

Q: Is the active ingredient Sildenafilo Cinfa the same as the one in Revatio?

A: Yes, Sildenafilo Cinfa contains Sildenafil, which is the same active ingredient found in the product Revatio. The two products are used to treat different medical conditions; Revatio is the brand name used for the pulmonary hypertension indication.

---

Q: Does taking Sildenafilo Cinfa make it difficult to drive or operate machinery?

A: Official warnings state that dizziness and visual disturbances, including visual colour distortion, are common side effects of the medicine. Regulatory warnings indicate that individuals must consider their own reaction to the medicine before driving, operating machinery, or performing tasks requiring mental alertness.

---

Q: What are the ingredients in Sildenafilo Cinfa besides the active substance?

A: Official regulatory documents list the full composition of the medicine, which includes the active substance, Sildenafil citrate, and various inactive ingredients known as excipients. These excipients are necessary for the tablet's stability, form, and delivery, but their specific names are detailed separately in the official product information.

---

Q: Why is it important to tell all healthcare providers about taking Sildenafilo Cinfa?

A: It is important to inform all healthcare providers about taking Sildenafilo Cinfa because of the risk of serious drug-drug interactions. For example, the combination with nitrates is strictly contraindicated due to the risk of severe, life-threatening hypotension. Other documented interactions may require a modification to the dose.

---

Q: Is Sildenafilo Cinfa a hormone or an aphrodisiac?

A: The medicine is pharmacologically classified as a selective Phosphodiesterase type 5 (PDE5) inhibitor. It does not act as a hormone and is not an aphrodisiac, as its mechanism requires the body’s natural response to sexual stimulation to become effective.

---

Q: How does Sildenafilo Cinfa affect blood flow outside of the penis?

A: Official information confirms that Sildenafil inhibits the PDE5 enzyme, which is present in blood vessels throughout the body, not just in the penis. This systemic effect means the medication influences blood flow in other areas, which is the reason why effects like flushing and temporary decreases in blood pressure are reported.

---

Q: Is there a risk of a serious allergic reaction to Sildenafilo Cinfa?

A: Known hypersensitivity (allergic reaction) to Sildenafil or any component of the tablet is listed as a contraindication in official safety documents. Serious hypersensitivity reactions, including anaphylactic reaction and shock, have been reported in post-marketing experience with the active substance.

---

Q: Is it possible for Sildenafilo Cinfa to interact with grapefruit or grapefruit juice?

A: Sildenafil is processed in the body by a specific liver enzyme. Evidence indicates that grapefruit juice can interfere with this enzyme, which may cause the level of sildenafil in the bloodstream to increase. An increased level of the medicine could potentially elevate the risk of experiencing side effects.

---

Q: Does Sildenafilo Cinfa affect fertility or sperm quality?

A: Non-clinical data from studies in healthy volunteers found no effect on the movement or shape of sperm after single doses of sildenafil. However, regulatory documents note that formal studies examining the long-term effect of the medication on male fertility have not been conducted.

---

Q: Is Sildenafilo Cinfa affected by drinking alcohol?

A: As a general principle, Sildenafilo Cinfa has the ability to lower blood pressure. The potential blood pressure-lowering effect of Sildenafilo Cinfa may be compounded by the use of alcohol, which could contribute to symptoms such as dizziness or lightheadedness.

---

Q: Can Sildenafilo Cinfa be used alongside other treatments for erectile dysfunction?

A: Official warnings state that the safety and effectiveness of combining Sildenafilo Cinfa with other therapies for erectile dysfunction, such as injectable or mechanical treatments, have not been formally studied. Therefore, this combination is generally not advised by regulatory sources.

---

Q: Are there any reports of Sildenafilo Cinfa causing back pain or muscle aches?

A: According to official side effect profiles, back pain and muscle aches (myalgia) are documented reactions to the medication. These effects have been reported in clinical trials, particularly in patients using sildenafil for the treatment of pulmonary arterial hypertension.

---

Q: What is the process for reporting a suspected side effect of Sildenafilo Cinfa?

A: Official regulatory information typically states that patients and healthcare professionals have the option to report suspected adverse reactions directly to the relevant national authority. This official reporting process allows health agencies to continuously monitor the safety of the medicine after it is made available to the public.

---

Q: Does Sildenafilo Cinfa interact with herbal supplements?

A: The safety of taking Sildenafilo Cinfa alongside herbal remedies or dietary supplements has generally not been formally studied. Regulatory guidance suggests that these substances are not tested in the same way as prescription medicines, making the interaction profile uncertain.

---

Q: Why do official documents mention the need for caution with a curved penis or Peyronie's disease?

A: Official documents advise caution for patients with a physical deformation of the penis, which includes a curved shape, cavernosal fibrosis, or conditions like Peyronie's disease. This caution is based on the potential risk of injury in these specific situations.

---

How to Store and Dispose of Sildenafilo Cinfa

Official regulatory documents define strict conditions for the storage and disposal of this medicine to ensure stability and safety.

---

Storage Requirements

Requirement	Official Directive
Temperature	Store below 30°C (Controlled Room Temperature).
Container Protection	Keep in the original package to protect from moisture and away from light.
Safety	Must be stored out of the sight and reach of children.

The product must be kept tightly closed in its original packaging and should not be stored in damp locations, such as a bathroom.

---

Disposal Instructions

Any unused or expired Sildenafilo Cinfa must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard the medicine via wastewater or household trash, as directed by regulatory guidelines.